Lv1
60 积分 2023-11-22 加入
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
1天前
待确认
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
4天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4天前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
5天前
已完结
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
5天前
已完结
Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study
5天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
7天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
7天前
已关闭
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib
7天前
已完结
皖公网安备34019202002308
